Drug Trial Radar · NCT07058012
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
79
Planned (sponsor's estimate)
Start
Apr 17, 2026
Primary completion
Apr 17, 2029
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- NSABP Foundation IncResearch network
- Sponsor type
- Research network
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.
Conditions
- Colo-rectal Cancer
Interventions
CemiplimabDrug
Cemiplimab 350mg intravenously
cemiplimab plus fianlimabDrug
Cemiplimab 350mg + Fianlimab 1600mg intravenously
cemiplimab + REGN7075Drug
Cemiplimab 350mg + REGN7075 2700mg intravenously
ctDNA testingOther
Eligible patients using results for ctDNA-positivity as obtained from a commercial assay run in any CLIA-certified lab will proceed to enrollment and begin treatment. All patients will have confirmation of ctDNA-positivity via the Signatera\^TM assay (Clinical Trial Assay), but treatment may proceed while awaiting confirmatory results.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clearance of cDNATime frame: From enrollment to 12 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of Florida
Gainesville, Florida · Recruiting
University of Iowa - Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Maryland Greenbaum
Baltimore, Maryland · Recruiting
Missouri Baptist
St Louis, Missouri · Recruiting
First Health of the Carolinas
Pinehurst, North Carolina · Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania · Recruiting
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania · Recruiting
Ballad Health Cancer Center - Kingsport
Kingsport, Tennessee · Recruiting
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah · Recruiting
University of Virginia Health
Charlottesville, Virginia · Recruiting
Bon Secours St. Francis Medical Center
Midlothian, Virginia · Recruiting
Virginia Commonwealth University - Massey
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.